p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma

Urologic Oncology

Volumn 6, Issue 2, 2001, Pages 63-67

  Olumi, Aria F ^a,e   Weidner, Noel ^b   Presti Jr , Joseph C ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

bcl 2; Immunohistochemistry; Ki 67; p53; Renal cell carcinoma

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; PRIORITY JOURNAL;

EID: 0035141999     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(00)00109-5     Document Type: Article

References (46)

1. Assignment of the human Ki-67 gene (MK167) to 10q25-qter
2. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
3. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation
4. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18
5. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
6. Large-scale normal cell death in the developing rat kidney and its reduction by epidermal growth factor
7. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair
8. JC, Rao PH, Chen Q, et al. Histopathological, cytogenetic, and molecular characterization of renal cortical tumors
9. Chromosome 17p deletions and p53 mutations in renal cell carcinoma
10. p53 function and dysfunction
11. Prognostic significance of morphologic parameters in renal cell carcinoma
12. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma
13. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas; no evidence for prognostic significance
14. Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma
15. Prognostic factors in renal-cell carcinoma; immunohistochemical detection of p53 protein versus clinico-pathological parameters
16. Prognostic value of Ki-67 expression in renal cell carcinomas
17. Quantitative evaluation of apoptosis and proliferation in renal cell carcinoma. Correlation to tumor subtype, cytological grade according to thoenes-classification and the occurrence of metastasis
18. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome
19. Expression of bcl-2 oncoprotein in renal cell tumours
20. Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma
21. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region
22. JC, Reuter VE, Cordon-Cardo C, Mazumdar M, Fair WR, Jhanwar SC. Allelic deletions in renal tumors; histopathological correlations
23. p53 mutations in human cancers
24. Novel DNA binding of p53 mutants and their role in transcriptional activation
25. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo
26. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53
27. Immunohistochemical analysis of p53 expression in malignant lymphomas
28. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form
29. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies
30. Expression of p53 protein in infiltrating and in-situ breast carcinomas
31. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation
32. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle
33. Identification of a p53-dependent negative response element in the bcl-2 gene
34. Does the immunophenotype of renal cell carcinoma correlate with its clinical stage?
35. Argyrophilic nucleolar organizer region counts and Ki-67 scores in human renal cell carcinoma
36. Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis
37. Expression of nm23 in cell lines derived from patients with metastatic renal cell carcinoma
38. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma
39. Tumor suppressor gene allelic loss in human renal cancers
40. p53, the cellular gatekeeper for growth and division
41. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
42. Immediate early up-regulation of bax expression by p53 but not TGF beta 1; a paradigm for distinct apoptotic pathways
43. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis
44. The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function
45. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma